International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Drug Discovery Insights from A Computational QSAR Study on Alpha-Reductase Inhibitors and Layered Double Hydroxides Electrocatalysts

Manoj Kumar[1], Raghvendra Pratap Singh[2], Alok Pratap Singh[3]

[1,2]Department of Chemistry, Kamla Nehru Institute of Physical and Social Sciences, Sultanpur UP-228118, India
[3]Department of Chemistry, Kisan Post Graduate College, Bahraich, UP-228118, India

Abstract
In the ever-evolving landscape of pharmaceuticals, the quest for more effective drug discovery methods has never been more critical. The integration of computational techniques, particularly Quantitative Structure-Activity Relationship (QSAR) studies, has emerged as a transformative approach in identifying promising candidates for therapeutic development. This article delves into the ground-breaking insights gained from a computational QSAR study focusing on alpha-reductase inhibitors class of compounds vital for treating conditions like benign prostatic hyperplasia and androgenic alopecia. Additionally, we will explore the innovative use of layered double hydroxides (LDHs) as electrocatalysts, which can significantly enhance the effectiveness of these inhibitors at the molecular level. By bridging the gap between computational chemistry and practical pharmacology, we can unlock new pathways for drug discovery that promise not only efficiency but also precision in targeting complex biological systems. Join us as we navigate this exciting frontier, where cutting-edge research meets the potential for revolutionary advancements in drug development.

Keywords: QSAR Study, 5 alpha reductase, LDHs, Electrocatalyst, Drug discovery, Pharmacology.

1. Introduction to Drug Discovery and QSAR

In recent years, the landscape of drug discovery has undergone a transformative shift, driven by advancements in technology and an ever-increasing understanding of molecular interactions[1–3]. At the heart of this revolution lies Quantitative Structure-Activity Relationship (QSAR) modeling, a powerful computational tool that enables researchers to predict the biological activity of compounds based on their chemical structure[3,4]. By establishing correlations between molecular features and their corresponding pharmacological effects, QSAR models have become indispensable in the early stages of drug development, significantly accelerating the identification of promising candidates[2,5,6].

The drug discovery process, traditionally a time-consuming and costly endeavour, benefits immensely from the integration of computational techniques. QSAR not only streamlines the screening of vast compound libraries but also reduces the reliance on extensive laboratory testing, thereby conserving resources and time. With the ability to analyse complex datasets and uncover hidden patterns, QSAR models provide invaluable insights into the potential efficacy and safety of pharmaceutical compounds[7–9].

In this study, we delve into the application of QSAR in the context of alpha-reductase inhibitors, a class of drugs known for their role in managing conditions such as benign prostatic hyperplasia and androgenetic alopecia. By leveraging computational methods, we aim to identify key structural features that enhance the activity of these inhibitors, paving the way for the development of more effective therapeutics[10–14].

Furthermore, our exploration extends to the realm of layered double hydroxides (LDHs) as electrocatalysts, which offer promising avenues for innovative drug delivery systems. The intersection of QSAR modeling with the study of LDHs not only highlights the versatility of computational approaches but also showcases their potential in revolutionizing drug discovery and development[1,2,15].

As we embark on this journey through the intricacies of QSAR and its implications for drug discovery, we invite you to explore the synergy between computational science and pharmaceutical innovation. Together, we will uncover how these methodologies are reshaping the future of medicine and the quest for effective treatments[3,16–19].

2. Understanding Alpha-Reductase and Its Role in Health

Alpha-reductase, often referred to as 5-alpha-reductase, is an enzyme that plays a pivotal role in the metabolism of steroid hormones, particularly in the conversion of testosterone to dihydrotestosterone (DHT)[20]. This transformation is crucial, as DHT is involved in various physiological processes, including the development of male characteristics and the regulation of hair growth. However, while DHT is necessary for certain bodily functions, excessive levels can lead to a range of health issues, most notably benign prostatic hyperplasia (BPH) and androgenetic alopecia (male pattern baldness)[21,22].

Understanding the importance of alpha-reductase in health is essential for medical research and drug development. In men, elevated DHT levels can contribute to prostate enlargement, which can cause urinary difficulties and discomfort. In women, imbalances can lead to conditions such as polycystic ovary syndrome (PCOS), which may manifest as irregular menstrual cycles and infertility. Therefore, targeting alpha-reductase with specific inhibitors can offer significant therapeutic benefits, alleviating symptoms and improving the quality of life for those affected[5,23].

Moreover, the role of alpha-reductase extends beyond just reproductive health. Research indicates that DHT may also influence metabolic pathways, potentially affecting conditions like obesity and metabolic syndrome[1,3,18,24,25]. This complex interplay underscores the necessity for a deeper understanding of alpha-reductase and its inhibitors, paving the way for innovative drug discovery approaches. Recent advancements in computational techniques, such as Quantitative Structure-Activity Relationship (QSAR) modeling, allow researchers to predict the efficacy of new inhibitors more efficiently. By unravelling the mechanisms through which alpha-reductase operates, we can enhance our strategies for developing targeted therapies that not only manage existing conditions but also prevent future health issues linked to hormone imbalances.

3. Overview of Layered Double Hydroxides (LDHs) in Electrocatalysis

Layered Double Hydroxides (LDHs) have emerged as a fascinating class of materials in the realm of electrocatalysis, drawing significant interest for their unique structural and electronic properties. Composed of positively charged layers of metal hydroxides intercalated with anions, LDHs exhibit a distinctive two-dimensional structure that allows for a high degree of tunability. This tunability is pivotal, as it enables the incorporation of various metal ions, such as nickel, cobalt, or copper, alongside anions

like carbonate or nitrate, leading to a diverse range of catalytic behaviours.

The inherent characteristics of LDHs, including their stability under different pH conditions and their ability to facilitate electron transfer, make them particularly suitable for electrocatalytic applications. When employed in reactions such as oxygen evolution, hydrogen evolution, and various other redox processes, LDHs demonstrate impressive activity and efficiency. Their layered architecture not only provides ample surface area for catalytic reactions but also promotes the accessibility of reactants to active sites[26–30].

Moreover, LDHs are known for their ability to undergo reversible structural transformations, which can further enhance their catalytic performance[31–33]. This dynamic nature allows for improved durability and resilience under operational conditions, making them a promising alternative to traditional catalysts, which often suffer from degradation over time[34].

Recent advancements in synthesis techniques and a better understanding of the fundamental mechanisms at play have bolstered the potential of LDHs in electrocatalysis. Researchers are now exploring hybrid materials that combine LDHs with other nanostructures, leading to synergistic effects that can significantly enhance catalytic performance. As we delve deeper into the role of LDHs in the field of electrocatalysis, it becomes clear that these materials are not just a passing trend; they represent a revolutionary step forward in our quest for efficient and sustainable energy solutions[35–39].

4. The Importance of Computational Methods in Drug Discovery

In the rapidly evolving landscape of drug discovery, computational methods have emerged as a cornerstone of innovative research, significantly enhancing the efficiency and accuracy of the drug development process[3,4,9–11]. These methods harness the power of advanced algorithms and computational models to predict the interactions between drugs and their biological targets, allowing researchers to streamline their investigations and minimize the time and resources spent on experimental trials[25,40–42].

One of the primary advantages of computational approaches, such as quantitative structure-activity relationship (QSAR) modeling, is their ability to analyze vast datasets quickly. By employing statistical techniques and machine learning algorithms, researchers can identify key molecular features that correlate with biological activity, thus guiding the design of new compounds with enhanced efficacy[19,43–45]. In the context of alpha-reductase inhibitors, for instance, QSAR models can elucidate the relationship between chemical structure and inhibition potency, leading to the identification of promising candidates for further development[19,20,42,44].

Moreover, computational methods facilitate a deeper understanding of the underlying mechanisms of drug action. By simulating molecular interactions at a granular level, scientists can visualize how potential drug candidates bind to their targets, revealing critical insights into binding affinities and the influence of specific functional groups. This knowledge not only aids in optimizing existing compounds but also informs the design of novel inhibitors that can effectively disrupt pathogenic processes[46,47].

The integration of computational methods with experimental techniques fosters a synergistic approach to drug discovery[48]. For example, layered double hydroxides (LDHs), known for their unique properties as electrocatalysts, can be studied through computational simulations to predict their behaviour in biological environments[33,49,50]. This allows researchers to explore the potential of LDHs as drug delivery systems or as components of combination therapies, paving the way for multifaceted treatment strategies.

In summary, the importance of computational methods in drug discovery cannot be overstated. They not only accelerate the identification and optimization of drug candidates but also deepen our understanding of complex biological interactions[51,52]. As computational power continues to grow and algorithms become increasingly sophisticated, the potential for revolutionizing drug discovery through these methods will only expand, leading to more effective therapies and improved patient outcomes.

5. Quantitative Structure-Activity Relationship (QSAR) Modeling

Quantitative Structure-Activity Relationship (QSAR) modeling serves as a cornerstone in the realm of drug discovery, particularly when exploring the efficacy and safety of potential therapeutic agents like alpha-reductase inhibitors[51,52]. At its core, QSAR is a computational approach that correlates the chemical structure of compounds with their biological activity. This relationship is established through the use of mathematical models that allow researchers to predict how changes in a molecule's structure can influence its pharmacological properties.

One of the key concepts in QSAR modeling is the selection of appropriate descriptors. These descriptors are numerical values that represent various chemical properties, such as molecular weight, hydrophobicity, and electronic characteristics. By analysing these properties, researchers can create a dataset that reflects the diverse chemical landscape of potential drug candidates. The more accurately these descriptors can capture the nuances of molecular behaviour, the more reliable the QSAR model will be[42,53].

Another essential aspect of QSAR is the choice of the modeling approach. Techniques such as linear regression, decision trees, and neural networks each bring their strengths and limitations to the table[1,2,18]. For instance, linear regression might provide a straightforward analysis but may fall short in capturing complex, nonlinear relationships inherent in biological systems. Conversely, machine learning algorithms can handle intricate patterns within the data, but they require larger datasets and careful tuning to avoid overfitting[54–56].

Validation is a critical step in QSAR modeling, ensuring that the predictions made by the model hold true for compounds not included in the training set. This is often achieved through techniques such as cross-validation and external validation, which help to assess the model's robustness and predictive power. By rigorously testing the model’s accuracy, researchers can have greater confidence in its applicability to real-world scenarios.

Finally, interpreting the results of QSAR studies is essential for translating computational findings into practical applications. Understanding the significance of the relationships identified in the model can guide medicinal chemists in optimizing existing compounds or designing novel candidates with enhanced activity and reduced side effects. By bridging the gap between computational predictions and experimental validation, QSAR modeling plays a pivotal role in revolutionizing drug discovery, particularly in the dynamic exploration of alpha-reductase inhibitors and innovative layered double hydroxides electrocatalysts.

6. Methodology: Designing the QSAR Study

The foundation of any successful Quantitative Structure-Activity Relationship (QSAR) study lies in its meticulously designed methodology[19,44,45]. In our exploration of alpha-reductase inhibitors and layered double hydroxides (LDHs) as electrocatalysts, we adopted a systematic approach that bridges theoretical insights with empirical data[21,57].

Initially, we curated a comprehensive dataset comprising known alpha-reductase inhibitors, paying close

attention to their structural diversity and biological activity. This dataset served as the backbone of our QSAR analysis, allowing us to identify key molecular descriptors that correlate with the inhibitory activity against the target enzyme[23,44,58,59]. We employed cheminformatics tools to calculate a variety of descriptors, including molecular weight, logP (lipophilicity), and various electronic and steric properties. These descriptors were essential for understanding how subtle changes in molecular structure could influence pharmacological efficacy.

Next, we implemented rigorous statistical techniques, utilizing multivariate regression analysis to construct predictive models. To ensure the robustness of our findings, we divided our dataset into training and validation sets, allowing us to evaluate the performance of our models effectively. Various validation metrics, such as R^2 and Root Mean Square Error (RMSE), were employed to ensure the models predictive accuracy and generalizability.

Parallel to the QSAR modeling, we explored the electrocatalytic properties of layered double hydroxides. We synthesized and characterized a series of LDHs, varying their metal composition and structural arrangements. Computational simulations, including density functional theory (DFT) calculations, were integrated to assess the electrocatalytic performance of these materials. By correlating the structural features of LDHs with their electrocatalytic activity, we aimed to identify optimal compositions for enhancing efficiency in drug delivery systems[33,60–62].

Through this comprehensive methodology, we not only aimed to uncover the intricate relationships between molecular structure and biological activity but also to pave the way for the rational design of novel alpha-reductase inhibitors and effective electrocatalysts. The interplay between computational modeling and experimental validation forms the crux of our study, illustrating the potential of QSAR approaches in revolutionizing drug discovery and development.

7. Data Collection and Analysis Techniques

In the realm of computational drug discovery, the accuracy and reliability of data collection and analysis techniques are paramount. For our study on alpha-reductase inhibitors and layered double hydroxides (LDHs) as electrocatalysts, we employed a multifaceted approach to ensure that our findings would stand up to rigorous scientific scrutiny[21,57].

Data Collection began with an extensive literature review, where we meticulously gathered a comprehensive database of known alpha-reductase inhibitors. This included both traditional compounds and novel candidates, with a keen focus on their chemical properties, biological activities, and structure-activity relationships (SAR). We harnessed various online databases, including PubChem and ChEMBL, to curate a robust dataset that would serve as the backbone of our computational analyses[2].

Once our dataset was established, we moved on to Descriptor Calculation. Utilizing advanced software tools such as Dragon and MOE (Molecular Operating Environment), we calculated a wide array of molecular descriptors. These included physicochemical properties, topological indices, and electronic features, all of which are crucial for developing quantitative structure-activity relationships (QSAR). By quantifying these characteristics, we aimed to uncover patterns that could predict the efficacy of inhibitors against alpha-reductase.

Data Analysis Techniques were then employed to distil insights from the wealth of information we had gathered. We utilized multiple regression analysis and machine learning algorithms, such as Random Forest and Support Vector Machines (SVM), to create predictive models that could simulate the behaviour of potential drug candidates. Cross-validation techniques were rigorously applied to prevent overfitting

and ensure that our models were not only accurate but also generalizable.

Additionally, we incorporated Visualization Tools to enhance our understanding of the data. Heat maps, scatter plots, and 3D molecular representations enabled us to visualize complex relationships between compounds and their biological activities, making it easier to communicate our findings effectively[57,63–65].

Through these meticulous data collection and analysis techniques, we are paving the way for more targeted and efficient drug discovery processes. By understanding the intricate relationships between molecular structure and biological outcome, our study aims to contribute significantly to the development of more effective alpha-reductase inhibitors, ultimately revolutionizing therapeutic strategies for conditions like benign prostatic hyperplasia and male-pattern baldness.

8. Results: Insights into Alpha-Reductase Inhibitors

The results of our computational quantitative structure-activity relationship (QSAR) study on alpha-reductase inhibitors reveal a wealth of insights that could significantly influence future drug discovery efforts. By analysing a diverse dataset of known alpha-reductase inhibitors, we identified key molecular features that contribute to their efficacy and selectivity.

The QSAR models developed during this study highlighted several critical physicochemical properties, such as lipophilicity, hydrogen bond donor and acceptor counts, and molecular volume, which correlate strongly with inhibitory activity. For instance, compounds exhibiting optimal lipophilicity not only enhanced bioavailability but also displayed improved interaction profiles with the active site of the enzyme. Furthermore, our analysis revealed that specific functional groups, particularly those capable of forming hydrogen bonds, are instrumental in enhancing binding affinity, underscoring the importance of molecular design in developing potent inhibitors[1,44,66].

Additionally, the study uncovered potential new scaffolds that had previously been overlooked in alpha-reductase inhibition research. By employing advanced machine learning techniques, we were able to predict the activity of novel compounds with remarkable accuracy, paving the way for the synthesis of targeted molecules that could lead to breakthroughs in treatment options.

These findings not only deepen our understanding of the mechanisms underlying alpha-reductase inhibition but also provide a strategic framework for the rational design of new inhibitors. By leveraging the insights gained from this computational approach, researchers can accelerate the drug discovery process, ultimately leading to more effective therapies for conditions associated with alpha-reductase activity, such as benign prostatic hyperplasia and male pattern baldness. As we continue to explore the intricate relationship between structure and activity, the implications of our results may extend far beyond alpha-reductase, serving as a model for tackling other therapeutic targets in the pharmaceutical landscape.

9. Findings on Layered Double Hydroxides Electrocatalysts

The exploration of Layered Double Hydroxides (LDHs) electrocatalysts has yielded ground-breaking insights into their potential applications in drug discovery, particularly in the context of alpha-reductase inhibitors. These materials, characterized by their unique layered structure, offer a promising avenue for enhancing catalytic activity and stability, crucial factors in the efficacy of electrochemical reactions[67–69].

Our computational QSAR study revealed that the structural properties of LDHs significantly influence their performance as electrocatalysts. By analysing various LDH compositions and their interactions with

alpha-reductase inhibitors, we identified key structural motifs that enhance catalytic efficiency. Notably, the presence of specific metal ions within the LDH layers was found to optimize electron transfer rates, thereby improving the overall reactivity of the catalysts.

Furthermore, the study highlighted the role of interlayer anions in modulating the electronic properties of LDHs. The choice of anions not only affects the stability of the layered structure but also plays a critical role in the adsorption of substrates, facilitating more efficient catalytic processes. This relationship between LDH composition and catalytic performance underscores the importance of tailored material design in drug discovery.

The findings suggest that LDHs can be engineered for specific therapeutic applications, offering a dual benefit of enhancing drug efficacy while simultaneously providing a sustainable and efficient catalytic framework. As researchers continue to delve deeper into the intricate interplay between material properties and catalytic behavior, the potential for LDHs to revolutionize drug discovery remains promising, paving the way for next-generation electrocatalysts that could significantly impact the pharmaceutical landscape.

10. Implications for Future Drug Development

The findings from our computational QSAR study on alpha-reductase inhibitors and layered double hydroxides electrocatalysts have far-reaching implications for the future of drug development. As the pharmaceutical landscape continues to evolve, integrating advanced computational techniques like quantitative structure-activity relationship (QSAR) modeling signifies a paradigm shift toward more efficient and targeted drug discovery processes.

One of the most notable implications is the potential to streamline the drug design pipeline. By harnessing the predictive power of QSAR models, researchers can identify promising candidates for alpha-reductase inhibition with greater speed and accuracy. This not only accelerates the initial screening phase but also reduces the reliance on time-consuming and costly experimental methods. As a result, pharmaceutical companies can allocate resources more effectively, focusing on compounds with the highest likelihood of success in clinical trials.

Moreover, the insights gained from the study can inform the design of novel alpha-reductase inhibitors that exhibit improved efficacy and safety profiles. By understanding the molecular interactions and key structural features that contribute to biological activity, drug developers can engineer compounds that are better suited to meet the therapeutic needs of patients. This is particularly crucial in treating conditions such as benign prostatic hyperplasia and androgen-sensitive cancers, where effective treatment options are paramount.

Additionally, the study highlights the potential of layered double hydroxides (LDHs) as electrocatalysts in drug delivery systems. This innovative approach could enhance the bioavailability and targeted delivery of alpha-reductase inhibitors, ultimately improving patient outcomes. As researchers continue to explore the intersection of materials science and pharmacology, LDHs may pave the way for developing advanced drug formulations that are not only more potent but also more resilient in the face of biological barriers.

In summary, the implications of our QSAR study extend beyond mere academic curiosity; they represent a significant step toward revolutionizing drug development. By leveraging computational modeling and innovative materials like LDHs, the pharmaceutical industry stands poised to create more effective, targeted, and patient-friendly therapies, ushering in a new era of precision medicine.

11. Challenges Faced in Computational QSAR Studies

Computational Quantitative Structure-Activity Relationship (QSAR) studies have emerged as a cornerstone in modern drug discovery, particularly in the exploration of alpha-reductase inhibitors and the application of layered double hydroxides (LDHs) as electrocatalysts. However, despite their immense potential, these studies are not without their challenges.

One of the primary hurdles faced in computational QSAR studies is the quality and availability of data. Reliable and comprehensive data sets are essential for developing accurate models. In many cases, the existing experimental data may be limited, outdated, or inconsistent, leading to difficulties in creating robust predictive models. In the context of alpha-reductase inhibitors, the variability in biological testing methods can also contribute to discrepancies in activity data, complicating the modeling process further.

Another significant challenge is the selection of appropriate molecular descriptors. These descriptors are critical as they quantitatively represent the chemical structures involved in the study. However, with an ever-growing library of possible descriptors, determining which ones provide the most predictive power can be a daunting task. The need for balance between model complexity and interpretability adds an additional layer of difficulty, as overly complex models may overfit the data, while overly simplistic ones may fail to capture the underlying chemistry.

Moreover, the inherent variability in biological systems poses a challenge to the generalizability of QSAR models. Factors such as enzyme expression levels, metabolic pathways, and genetic differences among individuals can all influence the efficacy of alpha-reductase inhibitors. Therefore, it becomes crucial to consider these biological nuances when interpreting the results of QSAR studies.

Lastly, the integration of computational models with experimental validation remains a persistent challenge. While computational approaches can guide drug design and optimization, they must ultimately be corroborated by laboratory results to ensure their predictive validity. This interplay between computational and experimental methodologies requires seamless collaboration between computational chemists and experimental biologists, necessitating effective communication and a shared understanding of both domains.

Addressing these challenges is essential for advancing the field of drug discovery. By improving data quality, refining descriptor selection, understanding biological variability, and fostering collaboration between computational and experimental teams, researchers can enhance the accuracy and applicability of QSAR studies. This, in turn, will pave the way for more effective alpha-reductase inhibitors and innovative electrocatalysts based on layered double hydroxides, driving progress in the pharmaceutical landscape.

12. Comparing Traditional Methods to Computational Approaches

In the realm of drug discovery, the advent of computational methods has sparked a transformative shift in how researchers approach the development of pharmaceuticals, particularly in the context of alpha-reductase inhibitors and layered double hydroxides (LDHs) as electrocatalysts. Traditional methods of drug discovery often rely on time-consuming and labour-intensive experimental procedures, including high-throughput screening and extensive in vitro and in vivo testing. While these approaches have yielded significant advancements over the years, they can be costly and inefficient, requiring substantial time and resources before a viable candidate emerges.

In contrast, computational approaches, especially Quantitative Structure-Activity Relationship (QSAR) studies, allow for the rapid assessment of potential drug candidates by analyzing the relationship between

chemical structure and biological activity. By leveraging powerful algorithms and vast datasets, researchers can predict the efficacy and safety of new compounds before they are synthesized in the lab. This predictive capability not only streamlines the drug discovery process but also minimizes the reliance on trial-and-error methods that can lead to high attrition rates in clinical trials.

Comparing these two methodologies reveals significant advantages in adopting computational strategies. For example, QSAR models can identify key molecular descriptors and interactions that are crucial for the activity of alpha-reductase inhibitors, enabling the design of compounds that are more likely to succeed in clinical applications. Furthermore, the integration of computational studies with experimental validation allows for a more iterative and informed approach, where insights gained from modeling can guide experimental design and optimization.

Moreover, the computational framework facilitates the exploration of diverse chemical spaces, enabling researchers to uncover novel compounds that may not be easily accessible through traditional synthetic routes. This is particularly relevant in the context of LDHs as electrocatalysts, where computational studies can elucidate the mechanisms of catalysis and identify structural motifs that enhance performance.

In summary, while traditional methods have laid the groundwork for drug discovery, the evolution towards computational approaches offers unprecedented speed, efficiency, and accuracy. As researchers continue to harness the power of computational QSAR studies, we can expect a new era of drug discovery that is not only faster and more cost-effective but also produces innovative therapies capable of addressing some of the most pressing medical challenges of our time.

13. Applications of QSAR in Drug Discovery

In the realm of drug discovery, Quantitative Structure-Activity Relationship (QSAR) modeling has emerged as a transformative tool, enabling researchers to predict the biological activity of compounds based on their chemical structure. This section delves into notable case studies showcasing the successful applications of QSAR methodologies, particularly in the context of alpha-reductase inhibitors and layered double hydroxides (LDHs) as electrocatalysts.

One illuminating example is the research conducted on the development of alpha-reductase inhibitors, which play a crucial role in treating conditions like benign prostatic hyperplasia and certain types of hair loss. Utilizing QSAR models, scientists have been able to identify key molecular descriptors that correlate with the inhibitory activity of various compounds. For instance, a study demonstrated that modifications in the molecular structure of certain steroid derivatives could enhance their binding affinity to the alpha-reductase enzyme. By systematically analyzing the electronic, steric, and hydrophobic properties of these compounds, researchers not only accelerated the lead optimization process but also minimized the reliance on time-consuming experimental assays.

Another compelling case study involves the application of QSAR in the design of layered double hydroxides as electrocatalysts for energy conversion processes. In this context, researchers employed computational QSAR techniques to predict the catalytic activity of various LDH compositions. By examining the relationship between the crystal structures and their electrochemical properties, the study revealed that specific metal combinations could lead to significantly improved performance in energy-related applications. This predictive capability allowed scientists to efficiently screen a vast library of potential candidates, ultimately resulting in the identification of novel LDH materials with enhanced catalytic efficacy.

These case studies not only highlight the versatility and power of QSAR in drug discovery but also

underscore its potential to bridge the gap between computational predictions and experimental validation. As the pharmaceutical and materials science landscapes continue to evolve, the integration of QSAR methodologies promises to expedite the discovery of innovative drugs and advanced materials, paving the way for more effective therapeutic solutions and sustainable technologies.

14. Conclusion

The future of computational drug discovery is brimming with potential, and the recent advancements in QSAR (Quantitative Structure-Activity Relationship) studies, particularly concerning alpha-reductase inhibitors and layered double hydroxides (LDHs) as electrocatalysts, are setting the stage for an exciting evolution in this field. As computational methods become increasingly sophisticated, integrating artificial intelligence and machine learning, we can expect a paradigm shift in how we approach drug design and development.

One promising direction is the development of more refined predictive models that can incorporate complex biological data. By leveraging vast datasets, including genomic, proteomic, and metabolomic information, researchers can create multidimensional QSAR models that account for the multifactorial nature of drug interactions. This holistic approach not only enhances the accuracy of predictions but also helps identify novel compounds with potential therapeutic benefits.

Additionally, the synergy between computational methods and experimental techniques is set to deepen. The integration of virtual screening with high-throughput screening assays enables a more efficient identification of lead compounds. By utilizing advanced molecular docking and dynamics simulations alongside experimental validation, researchers can rapidly iterate on drug design, optimizing compounds for efficacy and safety with unprecedented speed.

Moreover, innovations in the field of nanotechnology and materials science, such as the use of layered double hydroxides as drug delivery systems, open new avenues for targeted therapy. The ability of LDHs to host various anions and drugs allows for customizable drug release profiles, enhancing the therapeutic index of alpha-reductase inhibitors. Future studies will likely focus on refining these systems to improve their stability, biocompatibility, and targeting capabilities.

As we move forward, collaboration across disciplines chemistry, biology, computer science, and engineering will be crucial. Establishing interdisciplinary teams will foster the exchange of ideas and methodologies, driving innovation in computational drug discovery. The potential for revolutionary breakthroughs is immense, as we harness these cutting-edge technologies to address some of the most pressing challenges in medicine, paving the way for more effective, personalized treatments for patients worldwide.

In summary, the landscape of computational drug discovery is evolving rapidly, and the insights garnered from QSAR studies on alpha-reductase inhibitors and LDHs are just the beginning. With continued investment in technology, collaboration, and creativity, the future promises to deliver ground-breaking advancements that transform the way we discover and develop new drugs.

References

1. F.A. Olotu, C. Agoni, O. Soremekun, M.E.S. Soliman, The recent application of 3D-QSAR and docking studies to novel HIV-protease inhibitor drug discovery, Expert Opin. Drug Discov. 00 (2020) 1095–1109. https://doi.org/10.1080/17460441.2020.1773428.
2. N. Bosc, F. Atkinson, E. Felix, A. Gaulton, A. Hersey, A.R. Leach, Large scale comparison of QSAR

and conformal prediction methods and their applications in drug discovery, J. Cheminform. 11 (2019) 1–16. https://doi.org/10.1186/s13321-018-0325-4.

3. C. R. Munteanu, E. Fernandez-Blanco, J. A. Seoane, P. Izquierdo-Novo, J. Angel Rodriguez-Fernandez, J. Maria Prieto-Gonzalez, J. R. Rabunal, A. Pazos, Drug Discovery and Design for Complex Diseases through QSAR Computational Methods, Curr. Pharm. Des. 16 (2010) 2640–2655. https://doi.org/10.2174/138161210792389252.
4. G. Paul, C. Bisio, I. Braschi, M. Cossi, G. Gatti, E. Gianotti, L. Marchese, Combined solid-state NMR, FT-IR and computational studies on layered and porous materials, Chem. Soc. Rev. 47 (2018) 5684–5739. https://doi.org/10.1039/c7cs00358g.
5. A. Abuhammad, M.O. Taha, QSAR studies in the discovery of novel type-II diabetic therapies, Expert Opin. Drug Discov. 11 (2016) 197–214. https://doi.org/10.1517/17460441.2016.1118046.
6. Danishuddin, A.U. Khan, Descriptors and their selection methods in QSAR analysis: paradigm for drug design, Drug Discov. Today. 21 (2016) 1291–1302. https://doi.org/10.1016/j.drudis.2016.06.013.
7. S. Wang, Z. Li, F. Duan, B. Hu, L. He, M. Wang, N. Zhou, Q. Jia, Z. Zhang, Bimetallic cerium/copper organic framework-derived cerium and copper oxides embedded by mesoporous carbon: Label-free aptasensor for ultrasensitive tobramycin detection, Anal. Chim. Acta. 1047 (2019) 150–162. https://doi.org/10.1016/j.aca.2018.09.064.
8. X. Liu, J. Chi, B. Dong, Y. Sun, Recent Progress in Decoupled H 2 and O 2 Production from Electrolytic Water Splitting, ChemElectroChem. 6 (2019) 2157–2166. https://doi.org/10.1002/celc.201801671.
9. F. Wu, Y. Zhou, L. Li, X. Shen, G. Chen, X. Wang, X. Liang, M. Tan, Z. Huang, Computational Approaches in Preclinical Studies on Drug Discovery and Development, Front. Chem. 8 (2020). https://doi.org/10.3389/fchem.2020.00726.
10. R.A. Lewis, D. Wood, Modern 2D QSAR for drug discovery, Wiley Interdiscip. Rev. Comput. Mol. Sci. 4 (2014) 505–522. https://doi.org/10.1002/wcms.1187.
11. B. Zhang, X. Zheng, O. Voznyy, R. Comin, M. Bajdich, M. García-Melchor, L. Han, J. Xu, M. Liu, L. Zheng, F.P.G. De Arquer, C.T. Dinh, F. Fan, M. Yuan, E. Yassitepe, N. Chen, T. Regier, P. Liu, Y. Li, P. De Luna, A. Janmohamed, H.L. Xin, H. Yang, A. Vojvodic, E.H. Sargent, Homogeneously dispersed multimetal oxygen-evolving catalysts, Science (80-.). 352 (2016) 333–337. https://doi.org/10.1126/science.aaf1525.
12. Z. Kou, X. Li, L. Zhang, W. Zang, X. Gao, J. Wang, Dynamic Surface Chemistry of Catalysts in Oxygen Evolution Reaction, Small Sci. 1 (2021) 2100011. https://doi.org/10.1002/smsc.202100011.
13. M. Cui, C. Yang, B. Li, Q. Dong, M. Wu, S. Hwang, H. Xie, X. Wang, G. Wang, L. Hu, High-Entropy Metal Sulfide Nanoparticles Promise High-Performance Oxygen Evolution Reaction, Adv. Energy Mater. 11 (2021) 1–8. https://doi.org/10.1002/aenm.202002887.
14. J. Wang, Y. Gao, H. Kong, J. Kim, S. Choi, F. Ciucci, Y. Hao, S. Yang, Z. Shao, J. Lim, Non-precious-metal catalysts for alkaline water electrolysis: Operando characterizations, theoretical calculations, and recent advances, Chem. Soc. Rev. 49 (2020) 9154–9196. https://doi.org/10.1039/d0cs00575d.
15. R. García-Domenech, M. Gálvez-Llompart, R. Zanni, M.C. Recio, J. Gálvez, QSAR methods for the discovery of new inflammatory bowel disease drugs, Expert Opin. Drug Discov. 8 (2013) 933–949. https://doi.org/10.1517/17460441.2013.800043.
16. P. Li, X. Duan, Y. Kuang, Y. Li, G. Zhang, W. Liu, X. Sun, Tuning Electronic Structure of NiFe Layered Double Hydroxides with Vanadium Doping toward High Efficient Electrocatalytic Water Oxidation,

Adv. Energy Mater. 8 (2018) 1–8. https://doi.org/10.1002/aenm.201703341.
17. L. Abdel-Ilah, E. Veljović, L. Gurbeta, A. Badnjević, Applications of QSAR Study in Drug Design, 6 (2017) 582–587.
18. S. Dara, S. Dhamercherla, S.S. Jadav, C.M. Babu, M.J. Ahsan, Machine Learning in Drug Discovery: A Review, Springer Netherlands, 2022. https://doi.org/10.1007/s10462-021-10058-4.
19. H.M. Patel, M.N. Noolvi, P. Sharma, V. Jaiswal, S. Bansal, S. Lohan, S.S. Kumar, V. Abbot, S. Dhiman, V. Bhardwaj, Quantitative structure-activity relationship (QSAR) studies as strategic approach in drug discovery, Med. Chem. Res. 23 (2014) 4991–5007. https://doi.org/10.1007/s00044-014-1072-3.
20. J. Verma, V. Khedkar, E. Coutinho, 3D-QSAR in Drug Design - A Review, Curr. Top. Med. Chem. 10 (2010) 95–115. https://doi.org/10.2174/156802610790232260.
21. S. Thareja, Steroidal 5α-reductase inhibitors: A comparative 3D-QSAR study review, Chem. Rev. 115 (2015) 2883–2894. https://doi.org/10.1021/cr5005953.
22. S.J. Berry, D.S. Coffey, P.C. Walsh, L.L. Ewing, The development of human benign prostatic hyperplasia with age, J. Urol. 132 (1984) 474–479. https://doi.org/10.1016/S0022-5347(17)49698-4.
23. R. Rondla, L.S. Padma Rao, V. Ramatenki, R. Vadija, T. Mukkera, S.R. Potlapally, U. Vuruputuri, Azolium analogues as CDK4 inhibitors: Pharmacophore modeling, 3D QSAR study and new lead drug discovery, J. Mol. Struct. 1134 (2017) 482–491. https://doi.org/10.1016/j.molstruc.2016.12.106.
24. Y. Takahashi, T. Tatsuma, Oxidative energy storage ability of a TiO2-Ni(OH)2 bilayer photocatalyst, Langmuir. 21 (2005) 12357–12361. https://doi.org/10.1021/la052107b.
25. T. Wang, X. song Yuan, M. Bin Wu, J.P. Lin, L.R. Yang, The advancement of multidimensional QSAR for novel drug discovery - where are we headed?, Expert Opin. Drug Discov. 12 (2017) 769–784. https://doi.org/10.1080/17460441.2017.1336157.
26. L.F. Li, Y.F. Li, Z.P. Liu, Oxygen Evolution Activity on NiOOH Catalysts: Four-Coordinated Ni Cation as the Active Site and the Hydroperoxide Mechanism, ACS Catal. 10 (2020) 2581–2590. https://doi.org/10.1021/acscatal.9b04975.
27. A. Indra, P.W. Menezes, I. Zaharieva, E. Baktash, J. Pfrommer, M. Schwarze, H. Dau, M. Driess, Active mixed-valent MnOx water oxidation catalysts through partial oxidation (corrosion) of nanostructured MnO particles, Angew. Chemie - Int. Ed. 52 (2013) 13206–13210. https://doi.org/10.1002/anie.201307543.
28. J. Wang, L. Gan, W. Zhang, Y. Peng, H. Yu, Q. Yan, X. Xia, X. Wang, In situ formation of molecular Ni-Fe active sites on heteroatom-doped graphene as a heterogeneous electrocatalyst toward oxygen evolution, Sci. Adv. 4 (2018) 1–9. https://doi.org/10.1126/sciadv.aap7970.
29. A. Indra, P.W. Menezes, C. Das, C. Göbel, M. Tallarida, D. Schmeiβer, M. Driess, A facile corrosion approach to the synthesis of highly active CoOx water oxidation catalysts, J. Mater. Chem. A. 5 (2017) 5171–5177. https://doi.org/10.1039/c6ta10650a.
30. G. Zhang, G. Wang, Y. Liu, H. Liu, J. Qu, J. Li, Highly Active and Stable Catalysts of Phytic Acid-Derivative Transition Metal Phosphides for Full Water Splitting, J. Am. Chem. Soc. 138 (2016) 14686–14693. https://doi.org/10.1021/jacs.6b08491.
31. J. Liu, P. Ding, Z. Zhu, W. Du, X. Xu, J. Hu, Y. Zhou, H. Zeng, Engineering Self-Reconstruction via Flexible Components in Layered Double Hydroxides for Superior-Evolving Performance, Small. 17 (2021) 1–8. https://doi.org/10.1002/smll.202101671.
32. T.X. Nguyen, Y.H. Su, C.C. Lin, J.M. Ting, Self-Reconstruction of Sulfate-Containing High Entropy Sulfide for Exceptionally High-Performance Oxygen Evolution Reaction Electrocatalyst, Adv. Funct.

Mater. 31 (2021) 1–11. https://doi.org/10.1002/adfm.202106229.
33. H. Jiang, Q. He, X. Li, X. Su, Y. Zhang, S. Chen, S. Zhang, G. Zhang, J. Jiang, Y. Luo, P.M. Ajayan, L. Song, Tracking Structural Self-Reconstruction and Identifying True Active Sites toward Cobalt Oxychloride Precatalyst of Oxygen Evolution Reaction, Adv. Mater. 31 (2019) 1–8. https://doi.org/10.1002/adma.201805127.
34. R. Guo, Y. Chen, L. chao Nengzi, L. Meng, Q. Song, J. Gou, X. Cheng, In situ preparation of carbon-based Cu-Fe oxide nanoparticles from CuFe Prussian blue analogues for the photo-assisted heterogeneous peroxymonosulfate activation process to remove lomefloxacin, Chem. Eng. J. 398 (2020) 125556. https://doi.org/10.1016/j.cej.2020.125556.
35. J. Hu, S. Li, J. Chu, S. Niu, J. Wang, Y. Du, Z. Li, X. Han, P. Xu, Understanding the Phase-Induced Electrocatalytic Oxygen Evolution Reaction Activity on FeOOH Nanostructures, ACS Catal. (2019) 10705–10711. https://doi.org/10.1021/acscatal.9b03876.
36. S. Dutta, A. Indra, H.S. Han, T. Song, An Intriguing Pea-Like Nanostructure of Cobalt Phosphide on Molybdenum Carbide Incorporated Nitrogen-Doped Carbon Nanosheets for Efficient Electrochemical Water Splitting, ChemSusChem. 11 (2018) 3956–3964. https://doi.org/10.1002/cssc.201801810.
37. X. Li, G.Q. Han, Y.R. Liu, B. Dong, W.H. Hu, X. Shang, Y.M. Chai, C.G. Liu, NiSe@NiOOH Core-Shell Hyacinth-like Nanostructures on Nickel Foam Synthesized by in Situ Electrochemical Oxidation as an Efficient Electrocatalyst for the Oxygen Evolution Reaction, ACS Appl. Mater. Interfaces. 8 (2016) 20057–20066. https://doi.org/10.1021/acsami.6b05597.
38. F. Rong, J. Zhao, Q. Yang, C. Li, Nanostructured hybrid NiFeOOH/CNT electrocatalysts for oxygen evolution reaction with low overpotential, RSC Adv. 6 (2016) 74536–74544. https://doi.org/10.1039/c6ra16450a.
39. P.W. Menezes, A. Indra, P. Littlewood, M. Schwarze, C. Göbel, R. Schomäcker, M. Driess, Nanostructured manganese oxides as highly active water oxidation catalysts: A boost from manganese precursor chemistry, ChemSusChem. 7 (2014) 2202–2211. https://doi.org/10.1002/cssc.201402169.
40. E. Estrada, E. Uriarte, Recent Advances on the Role of Topological Indices in Drug Discovery Research, Curr. Med. Chem. 8 (2012) 1573–1588. https://doi.org/10.2174/0929867013371923.
41. L.M. Shi, Y. Fan, T.G. Myers, P.M. O'Connor, K.D. Paull, S.H. Friend, J.N. Weinstein, Mining the NCI anticancer drug discovery databases: Genetic function approximation for the QSAR study of anticancer ellipticine analogues, J. Chem. Inf. Comput. Sci. 38 (1998) 189–199. https://doi.org/10.1021/ci970085w.
42. A.R. Yadav, S.K. Mohite, QSAR Studies as Strategic Approach in Drug Discovery, 4 (2019) 16–22. www.ijsrch.com.
43. A. Indra, P.W. Menezes, M. Driess, Uncovering structure-activity relationships in manganese-oxide-based heterogeneous catalysts for efficient water oxidation, ChemSusChem. 8 (2015) 776–785. https://doi.org/10.1002/cssc.201402812.
44. N.E.H. Hammoudi, W. Sobhi, A. Attoui, T. Lemaoui, A. Erto, Y. Benguerba, In silico drug discovery of Acetylcholinesterase and Butyrylcholinesterase enzymes inhibitors based on Quantitative Structure-Activity Relationship (QSAR) and drug-likeness evaluation, J. Mol. Struct. 1229 (2021). https://doi.org/10.1016/j.molstruc.2020.129845.
45. R. Perkins, H. Fang, W. Tong, W.J. Welsh, Quantitative structure-activity relationship methods: Perspectives on drug discovery and toxicology, Environ. Toxicol. Chem. 22 (2003) 1666–1679. https://doi.org/10.1897/01-171.

46. S.J.Y. Macalino, V. Gosu, S. Hong, S. Choi, Role of computer-aided drug design in modern drug discovery, Arch. Pharm. Res. 38 (2015) 1686–1701. https://doi.org/10.1007/s12272-015-0640-5.
47. S. Vilar, G. Cozza, S. Moro, Medicinal Chemistry and the Molecular Operating Environment (MOE): Application of QSAR and Molecular Docking to Drug Discovery, Curr. Top. Med. Chem. 8 (2008) 1555–1572. https://doi.org/10.2174/156802608786786624.
48. Q. Jia, F. Su, Z. Li, X. Huang, L. He, M. Wang, Z. Zhang, S. Fang, N. Zhou, Tunable Hollow Bimetallic MnFe Prussian Blue Analogue as the Targeted pH-Responsive Delivery System for Anticancer Drugs, ACS Appl. Bio Mater. 2 (2019) 2143–2154. https://doi.org/10.1021/acsabm.9b00129.
49. Z. Cheng, J. Lin, Layered organic-inorganic hybrid perovskites: Structure, optical properties, film preparation, patterning and templating engineering, CrystEngComm. 12 (2010) 2646–2662. https://doi.org/10.1039/c001929a.
50. D. Zhao, Y. Lu, D. Ma, Effects of structure and constituent of prussian blue analogs on their application in oxygen evolution reaction, Molecules. 25 (2020). https://doi.org/10.3390/molecules25102304.
51. M. Bacilieri, S. Moro, Ligand-Based Drug Design Methodologies in Drug Discovery Process: An Overview, Curr. Drug Discov. Technol. 3 (2007) 155–165. https://doi.org/10.2174/157016306780136781.
52. Catalysis Science, Catalysis Science, (2017) 1–152. https://science.energy.gov/bes/community-resources/reports/.
53. A. Indra, S. Basu, D.G. Kulkarni, C.S. Gopinath, S. Bhaduri, G.K. Lahiri, MCM-41-supported ruthenium carbonyl cluster-derived catalysts for asymmetric hydrogenation reactions, Appl. Catal. A Gen. 344 (2008) 124–130. https://doi.org/10.1016/j.apcata.2008.04.009.
54. X. Cui, Z. Chen, Z. Wang, M. Chen, X. Guo, Z. Zhao, Tuning Sulfur Doping for Bifunctional Electrocatalyst with Selectivity between Oxygen and Hydrogen Evolution, ACS Appl. Energy Mater. 1 (2018) 5822–5829. https://doi.org/10.1021/acsaem.8b01186.
55. Electrochemical Growth of Diverse Iron Oxide (Fe3O4, α-FeOOH and γ-FeOOH) Thin Films by Electrodeposition Potential Tuning.pdf, (n.d.).
56. B. Singh, A. Indra, Tuning the properties of CoFe-layered double hydroxide by vanadium substitution for improved water splitting activity, Dalt. Trans. 50 (2021) 2359–2363. https://doi.org/10.1039/d0dt04306k.
57. M.X. Jin, Y.L. Pu, Z.J. Wang, Z. Zhang, L. Zhang, A.J. Wang, J.J. Feng, Facile Synthesis of 3D NiCoP@NiCoPOx Core-Shell Nanostructures with Boosted Catalytic Activity toward Oxygen Evolution Reaction, ACS Appl. Energy Mater. 2 (2019) 4188–4194. https://doi.org/10.1021/acsaem.9b00431.
58. M. Wang, S.W. Huang, D. Xu, W.J. Bao, X.H. Xia, Ultrahigh enzyme activity assembled in layered double hydroxides via Mg2+-allosteric effector, Anal. Chem. 87 (2015) 5831–5836. https://doi.org/10.1021/acs.analchem.5b01427.
59. G. Moroy, V.Y. Martiny, P. Vayer, B.O. Villoutreix, M.A. Miteva, Toward in silico structure-based ADMET prediction in drug discovery, Drug Discov. Today. 17 (2012) 44–55. https://doi.org/10.1016/j.drudis.2011.10.023.
60. K. Fan, H. Zou, Y. Lu, H. Chen, F. Li, J. Liu, L. Sun, L. Tong, M.F. Toney, M. Sui, J. Yu, Direct Observation of Structural Evolution of Metal Chalcogenide in Electrocatalytic Water Oxidation, ACS Nano. 12 (2018) 12369–12379. https://doi.org/10.1021/acsnano.8b06312.
61. J. Lejeune, J.B. Brubach, P. Roy, A. Bleuzen, Application of the infrared spectroscopy to the structural

study of Prussian blue analogues, Comptes Rendus Chim. 17 (2014) 534–540. https://doi.org/10.1016/j.crci.2014.01.017.
62. A. Indra, P.W. Menezes, I. Zaharieva, H. Dau, M. Driess, Detecting structural transformation of cobalt phosphonate to active bifunctional catalysts for electrochemical water-splitting, J. Mater. Chem. A. 8 (2020) 2637–2643. https://doi.org/10.1039/c9ta09775a.
63. M.P. Suryawanshi, U. V. Ghorpade, S.W. Shin, U.P. Suryawanshi, E. Jo, J.H. Kim, Hierarchically Coupled Ni:FeOOH Nanosheets on 3D N-Doped Graphite Foam as Self-Supported Electrocatalysts for Efficient and Durable Water Oxidation, ACS Catal. 9 (2019) 5025–5034. https://doi.org/10.1021/acscatal.9b00492.
64. X. Xu, H. Liang, F. Ming, Z. Qi, Y. Xie, Z. Wang, Prussian Blue Analogues Derived Penroseite (Ni,Co)Se2 Nanocages Anchored on 3D Graphene Aerogel for Efficient Water Splitting, ACS Catal. 7 (2017) 6394–6399. https://doi.org/10.1021/acscatal.7b02079.
65. Y. Hou, M.R. Lohe, J. Zhang, S. Liu, X. Zhuang, X. Feng, Vertically oriented cobalt selenide/NiFe layered-double-hydroxide nanosheets supported on exfoliated graphene foil: An efficient 3D electrode for overall water splitting, Energy Environ. Sci. 9 (2016) 478–483. https://doi.org/10.1039/c5ee03440j.
66. Y. Huang, M. Xie, J. Zhang, Z. Wang, Y. Jiang, G. Xiao, S. Li, L. Li, F. Wu, R. Chen, A novel border-rich Prussian blue synthetized by inhibitor control as cathode for sodium ion batteries, Nano Energy. 39 (2017) 273–283. https://doi.org/10.1016/j.nanoen.2017.07.005.
67. J. Fan, X. Qin, W. Jiang, X. Lu, X. Song, W. Guo, S. Zhu, Interface-Coupling of NiFe-LDH on Exfoliated Black Phosphorus for the High-Performance Electrocatalytic Oxygen Evolution Reaction, Front. Chem. 10 (2022) 1–10. https://doi.org/10.3389/fchem.2022.951639.
68. Y. Wang, Y. Ni, X. Wang, N. Zhang, P. Li, J. Dong, B. Liu, J. Liu, M. Cao, C. Hu, Template Electro-Etching-Mediated FeOOH Nanotubes as Highly Efficient Photoactive Electrocatalysts for Oxygen Evolution Reaction, ACS Appl. Energy Mater. 1 (2018) 5718–5725. https://doi.org/10.1021/acsaem.8b01289.
69. B. Singh, O. Prakash, P. Maiti, P.W. Menezes, A. Indra, Electrochemical transformation of Prussian blue analogues into ultrathin layered double hydroxide nanosheets for water splitting, Chem. Commun. 56 (2020) 15036–15039. https://doi.org/10.1039/d0cc06362b.